About GigaGen
GigaGen is a company based in San Francisco (United States) founded in 2011 was acquired by Grifols in March 2021. GigaGen has raised $36.13 million across 19 funding rounds from investors including NIH, Grifols and HHS. The company has 36 employees. GigaGen offers products and services including GIGA-564 and GIGA-2339. GigaGen operates in a competitive market with competitors including Sana Biotechnology, TScan Therapeutics, Janux Therapeutics, Carisma Therapeutics and Kronos Bio, among others.
- Headquarter San Francisco, United States
- Employees 36
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website gigagen.com
- Social LinkedIn X
- Acquired by Grifols (Mar 2021)
- Legal Name Gigagen Inc.
Products & Services of GigaGen
GigaGen offers a comprehensive portfolio of products and services, including GIGA-564 and GIGA-2339.
Targets CTLA-4 for treating advanced solid tumors with improved efficacy.
Therapy for Hepatitis B virus to neutralize infection and aid treatment.
Funding Insights of GigaGen
GigaGen has successfully raised a total of $36.13M across 19 strategic funding rounds. The most recent funding activity was a Grant round of $3 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $36.1M
- Total Rounds 19
- Last Round Grant — $3.0M
- First Round $201,616
(Mar 2011)
- Investors Count 5
Latest 10 of 19 funding rounds of GigaGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $3.0M | Grant | – | – | |
| Jul 2017 | $36.1M | Series B | – | – | – |
| Jul 2016 | $1.5M | Grant | – | – | |
| Mar 2016 | $750,198 | Grant | – | – | |
| Jun 2015 | $3.5M | Grant | – | – | |
| May 2015 | $224,819 | Grant | – | – | |
| Sep 2014 | $217,469 | Grant | – | – | |
| Aug 2014 | $249,077 | Grant | – | – | |
| Sep 2012 | $1.0M | Grant | – | – | |
| Sep 2012 | $1.1M | Grant | – | – |
6 investors in total: 6 institutional.
Investors in GigaGen
GigaGen has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include NIH, Grifols and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Energy sources and policies are managed by the DOE. | 1977 | energy.gov | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Plasma-derived therapies are developed to treat multiple diseases. | 1909 | grifols.com | Barcelona, Spain | |
- | – | osti.gov | - |
Investor details for GigaGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GigaGen
10 people are tracked at GigaGen (5 in leadership, 5 in team); the tracked headcount is 36.
| Name | Role | Group |
|---|---|---|
Catherine Medina | VP, Operations | Leadership |
Jan Fredrik Simons | Senior Director, Technology | Leadership |
Kyle Carter | Associate Director, Technology Development | Leadership |
Renee Leong | Director, Operations | Leadership |
Hongjun Yue | Director | Leadership |
Carter Keller | Grifols' SVP - Gigagen | Team |
Kacy Stadtmiller | Project Manager | Team |
Chelsea Nahavandi | Senior Scientist I | Team |
Hanz Olonan | Quality Assurance Manager | Team |
Jenny Chau | Senior Research Associate | Team |
Complete people profiles for GigaGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GigaGen
4 dated milestones of GigaGen across 10 years, from founding to its latest funding, stage changes and deals.
- Founded GigaGen is founded.
- Funding First funding round of $202K.
- Funding Latest funding round, Grant, of $3.0M.
- Exit Acquired by Grifols.
Competitors of GigaGen
GigaGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, TScan Therapeutics, Janux Therapeutics, Carisma Therapeutics and Kronos Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821.0M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| januxrx.com | 2017 | San Diego, United States | $181.0M | 59 | Immunotherapeutics for cancer treatment are developed to target solid tumors. | |
| carismatx.com | 2016 | Philadelphia, United States | $3.9M | 54 | Chimeric antigen receptor macrophages are developed for cancer treatment. | |
| kronosbio.com | 2017 | San Mateo, United States | $271.0M | 97 | Small molecule therapeutics for cancer treatment are developed. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. | |
| asherbio.com | 2019 | San Francisco, United States | $218.5M | – | Developer of immunotherapies for the treatment of cancer and autoimmune diseases | |
| boundlessbio.com | 2018 | San Diego, United States | $252.0M | 29 | Therapeutics for cancer are developed by targeting ecDNA. |
Detailed competitors of GigaGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GigaGen
The website of GigaGen (gigagen.com) receives about 2.6K visits a month and ranks #8,258,525 among all websites worldwide, #7,311 in Biotechnology and Pharmaceuticals.
- Monthly visits2.6K
▲ 41.3% vs previous month
- Global rank#8,258,525
among all websites
- Category rank#7,311
Health · Biotechnology and Pharmaceuticals
- Bounce rate63%
- Pages per visit1.8
- Average visit40 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with GigaGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| adaptivebiotech.com | 100% | 63.9K | #807,876 | View details | |
research.chop.edu | research.chop.edu | 80% | – | – | – |
globalbiodefense.com | globalbiodefense.com | 77% | – | #1,776,107 | – |
| natera.com | 72% | 1.1M | #40,970 | View details |
Latest news on Gigagen
Complete news archive for GigaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to GigaGen
10 companies that operate in the same segment as GigaGen (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 | |
Developer of CAAR T cells for B cell-mediated autoimmune diseases | 2017 | Radnor, Pennsylvania, United States | USD 88.26 M | – | 161 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GigaGen
GigaGen was founded in 2011.
GigaGen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
GigaGen is a funded company, having raised a total of $36.13M across 19 funding rounds to date. The company's 1st funding round was a Grant of $1.12M, raised on Mar 2011.
GigaGen has 36 employees.
Founded in 2011 and based in San Francisco, United States, GigaGen operates in the biotechnology sector. T-cell and antibody-based therapeutics are developed using a high-throughput platform that incorporates microfluidics, bioinformatics, next-generation sequencing, and genetic engineering. Full-length natively paired antibodies and T-cell receptors are produced from single primary B or T cells, with integration of clonal identity, function, and target binding data.
GigaGen's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.
GigaGen offers GIGA-564 and GIGA-2339.
GigaGen has 6 investors. Key investors include NIH, Grifols, HHS, DOE, and National Science Foundation.
GigaGen operates through Gigagen Inc..
Yes. GigaGen was acquired by Grifols in March 2021.